

Effect of experimentally induced diabetes mellitus on serum leptin level and the role of insulin replacement therapy

Nabil A. Soliman

Department of Zoology, Faculty of science, Zagazig University.

Abstract

The regulation of circulating leptin concentration is multifactorial and still understood. Therefore, the present study was designed: (1) to demonstrate the effect of gender on leptin concentration in intact control rats, (2) to evaluate the relationship between serum leptin concentration, serum insulin level and body weight in control rats and streptozotocin (STZ) diabetic rats (untreated and treated with insulin). A total number of 48 healthy adult albino rats of both sexes (24males& 24 females) were used in this study. The animals were divided equally into four groups, each group was subdivided equally into -male and female subgroups. Group 1(G₁): served as control group, group 2(G₂): experimental diabetics group (not treated) and group 3(G₃) & group 4(G₄): experimental diabetic group treated with insulin for 2 and 21 days. These groups were examined for the following parameters: body weight, blood glucose level, serum insulin and leptin concentration. It was found that serum leptin level was significantly higher in female than in male control group. However, this difference could not be detected in between male and female rats in all other studied groups. Moreover, a strong positive correlation was found between leptin concentration and insulin hormone level, and body weight in control male and female rats. STZ-induced diabetes associated with a significant rapid decrease in circulating leptin concentration (G₂), this decrease was accompanied with a significant decrease in both serum insulin level and body weight, then, it was rapidly reversed by insulin treatment for 2days (G₃) and 21 days (G₄). There was also a positive correlation between serum leptin concentration, body weight and serum insulin level in this diabetic group. However, leptin was found to change in an inverse proportion to the variation in blood glucose concentration in both male and female diabetic groups. The direct relationship of serum leptin concentration to serum insulin concentration and the inverse relationship of leptin concentration to blood glucose level were preserved in both male and female insulin replacement therapy groups.

In conclusion, in adult albino rats, several factors are involved in the regulation of circulating leptin level such as gender, body weight, blood glucose level and serum insulin concentration.

Introduction

The discovery of the obese gene in the mouse and its conserved homologue in humans has led many researchers to work hardly to find out the factors which could regulate the expression of leptin gene and in turn could regulate metabolism and behavior (Saladine *et*

al., 1996). Leptin was first described as an adiposity derived signaling factor, which, after interaction with specific receptors, induces a pleiotropic response including control of body weight and energy expenditure. Although research has moved ahead rapidly there

are still more questions about the regulatory pathways that control leptin and modulate leptin expression (Auwerx and Stales, 1998).

Several lines of evidence suggested that the hypothalamus is a critical target for the satiety effect of leptin. This effect may be mediated partly by inhibition of neuropeptide Y (NPY) which is a potent stimulator of food intake (Erickson *et al.*, 1996). Other candidates of which activity could be modulated by leptin and which are active in the brain are melanocyte stimulating hormone (Huszer *et al.*, 1997), glucagon-like peptide, corticotropin releasing hormone or related factor urocortin, and melanin concentrating hormone. (Spina *et al.*, 1996).

A remarkable gender difference in serum leptin levels in both human and animal studies were reported. It was found that intact female rats had a higher serum leptin level than intact male rats (Yacout *et al.*, 2000). Moreover, profound gender differences in circulating leptin was documented in adult humans (Havel *et al.*, 1996), children (Lahlou *et al.*, 1997), and healthy subjects and young patients with insulin dependant diabetes mellitus (IDDM) (Verroti *et al.*, 1998).

Previous studies reported that the amount of leptin mRNA in adipocytes correlates with body weight (Hamilton *et al.*, 1995). It was found that circulating leptin concentration is elevated in the obese state; decrease following weight loss and increase again with weight (Nicklas *et al.*, 1997). Moreover, it was reported by Considine *et al.* (1996) that a reduction of 10% in body weight is associated with 53% reduction in serum leptin. Even a 4% reduction in body weight over a period of 7 days resulted in 61% decrease in leptin values in both sexes (Dubuc *et al.*, 1998). In addition, Caro *et al.* (1996)

reported that a small (10%) increase in body weight results in a 300% increase in serum leptin.

A strong positive correlation was reported between serum leptin concentration and body fat content and serum insulin level (McGreoger *et al.*, 1996). In addition, some but not all investigators found that insulin is a potent regulator of plasma leptin level regardless of their relationship with body weight and total body fat (Ahren *et al.*, 1997 and Kiess *et al.*, 1998). However, other investigators suggested that insulin does not stimulate leptin production (Dagog-Jack *et al.*, 1996). Regulation of (ob) gene expression by insulin is also supported by findings that (ob) gene expression is reduced in insulin dependent diabetes which is accompanied by hypoinsulinemia (Sivitz *et al.*, 1996 and Sivitz *et al.*, 1998). However, Tuominen *et al.* (1997) demonstrated that leptin levels were higher in insulin dependent diabetes mellitus. In addition, Verroti *et al.* (1998) showed that type I diabetes does not modify serum leptin concentration.

Some studies showed that insulin therapy resulted in normalization of lower leptin levels in diabetic animals (Mac Dougard *et al.*, 1998), while others did not (Backer *et al.*, 1995).

Because of the variability of information mentioned and the contradiction of reports about some of the factors that could regulate the serum leptin levels, this study was designed to:

1. Demonstrate the effect of gender on leptin concentration in the intact control group and evaluate the effect of gender under the influence of some metabolic disorders as experimentally-induced diabetes mellitus (untreated and treated with insulin).
2. Evaluate the relationship between leptin concentration, serum insulin level and body weight in control

intact rats, experimentally diabetic rats (untreated and treated with insulin).

3. Study the effect of experimental diabetes and Insulin replacement therapy for 2 days and for 15 days on serum leptin concentration.

Material & Methods

Experimental Animals:

A total number of 48 healthy adult albino rats of both sexes (24 adult males & 24 adult females) weighting 215- 318 gms were used for this study. The animals were kept in steel wire cages at the animal house throughout the study, and fed the same type of food to avoid the effect of different food elements on the experiments, the diet consisted of mixed commercial rat laboratory chow. They had free access to water and kept at room temperature. The animals were divided equally into four groups:

G₁: This group consisted of 6 male and 6 female rats and served as a control group.

G₂: This group consisted of 6 male and 6 female rats in which diabetes was experimental induced by intravenous injection of freshly prepared solution of streptozotocin (STZ) (Sigma, 65 mg/kg, dissolved in 0.2 mmol/l sodium citrate, pH 4.5) (Lutz and Pardridge, 1993). For 48 hours after treatment with STZ, the water supply was supplemented with 5% glucose to minimize deaths from acute hypoglycemia (Harry *et al.*, 1993). Within 48 to 72 hours after injection, the criteria of diabetes such as weight loss, glycosuria and hyperglycemia were observed in these rats.

G₃ and G₄ consisted of 12 male and 12 female diabetic rats for each group in which diabetes was induced as previously mentioned in G₂. Diabetic rats were treated with regular insulin

(R) (Eli Lilly company, Indianapolis, IN) and NPH (N) insulin (Nordisk Gentofte A/S Laboratorium, Denmark.) (2 U R at diagnosis of diabetes and then 1R/3N at 6 PM and 1R/1N at 9 AM daily) subcutaneously for 2 days after induction of diabetes (Sivitz *et al.*, 1998), in G₃, and for 21 days in G₄.

The initial and final body weights were recorded for rats in all groups (before and after induction of diabetes).

Sampling Of Blood:

Blood samples were obtained by decapitation of rats after lightly anesthetized with pentobarbital (90mg/kg) between 9-11 A.M to avoid the circadian rhythm in serum leptin. Blood glucose was determined in all groups using Reflolux reflectance photometers Boehringer Mannheim UK (Diagnostic & Biochemicals) Ltd. Bell Lanen, Lewes, East Sussex, BN7 1LG GB. The serum was separated by allowing the blood to clot then centrifuged at 3000 rpm for 10 minutes and stored deep frozen at -20°C until used for: 1- estimation of serum insulin level in all groups by using (MEDGENIX-INS-EASIA-Enzyme Amplified Sensitivity Immunoassay) Kits: For the measurement of Insulin in serum by Immunoenzymetric Assay. BioSource Europe S.A. 2- Determination of serum leptin levels in all groups by using active leptin ELISA kit (DSL-10-23100 Diagnostic Systems Laboratories, Inc. Corporate Headquarters, 445 Medical center Blvd. Webster, Texas, USA).

Statistical analysis:

All data were expressed as mean \pm SE and statistically analyzed according to Yamane (1970). A P value <0,05 was considered significant.

RESULTS

Table (1) Fig. (1) illustrate the effect of gender on serum leptin level in

control, diabetic and insulin treated diabetic male and female rats. It was found that the mean value of leptin serum concentration in the control female group (1.80 ± 0.052 ng/ml, $P < 0.001$) was statistically higher than in the control male group (1.25 ± 0.05 ng/ml). However, this difference could not be detected in between male and female in all other studied groups [(0.46 ± 0.042 ; 0.56 ± 0.066 ng/ml), $P > 0.05$, respectively for diabetic group), (1.02 ± 0.05 ; 1.1 ± 0.07 ng/ml, $P > 0.05$, respectively, for 2 days insuline replacement) and (1.52 ± 0.12 ; 1.6 ± 0.1 ng/ml, $P > 0.05$ respectively, for 21 days insulin replacement)].

Table (2,3) show serum leptin concentration, insulin level, blood glucose level and body weight in diabetic (untreated) and diabetic treated with insulin replacement for 2 and 21 days in male and female rats compared with the control group. It was found that the mean leptin concentration in both male and female diabetic rats [(0.46 ± 0.042 ; 0.56 ± 0.066 ng/ml, respectively) was significantly lower than in the male and female control groups [(1.25 ± 0.05 ; 1.80 ± 0.052 ng/ml, respectively)] (Fig.1).

It was observed that the decrease in serum leptin concentration in diabetic male and female rats was significantly corrected with insulin replacement therapy for 2 and 21 days to reach a mean value [(1.02 ± 0.052 ; 1.1 ± 0.07 ng/ml, and (1.52 ± 0.12 ; 1.6 ± 0.1 ng/ml, respectively, $P < 0.001$), nearer to that of normal control rats specially with 21 days insulin replacement. As regards, the changes in serum insulin level, there was no significant difference between male and female control groups, indicating that, insulin may not be responsible for the gender difference in serum leptin concentration observed in Table (1).

However, it was noted that the mean value of insulin level in both male and female diabetic groups was lower than that of control male and female groups [(1.5 ± 0.56 ; 1.36 ± 0.4 μ IU/ml) respectively, for diabetic groups) and [(30.4 ± 1.4 ; 31.3 ± 2.56 μ IU/ml, respectively, for control groups)].

Insulin replacement therapy for 2 days and 21 days was found to cause statistically significant increase in serum insulin concentration in both male and female rats [(51.4 ± 4.8 ; 56.4 ± 5.8 μ IU/ml, respectively, for 2 days group, $P < 0.001$) and (97.4 ± 6.4 ; 86.3 ± 7.4 μ IU/ml, respectively, for 21 days group)] when compared to either control or diabetic groups (Fig. 2).

Regarding the changes in blood glucose level, it was found that, there was a statistically significant increase in blood glucose level in diabetic male and female groups [(342.7 ± 34.5 ; 338.5 ± 21.6 mg/dl, respectively)], when compared with the control groups [(89.5 ± 4.2 ; 92.8 ± 4.9 mg/dl, respectively)].

Insulin replacement therapy for 2 and 21 days was associated with a highly significant decrease in blood glucose level in male and female rats [(70.2 ± 5.04 , 72.0 ± 4.4 mg/dl, respectively, for 2 days group) and (60.5 ± 2.3 , 66.8 ± 2.8 mg/dl, respectively, for 21 days group)], when compared with diabetic groups (Fig. 3).

It was also found that, the body weight was significantly decreased in diabetic male and female rats (271.8 ± 6.3 , 214.7 ± 7.4 gms, respectively). Treatment of diabetic male and female rats with insulin for 2 and 21 days resulted in a significant correction of the reduction in body weight in both male and female rats compared to diabetic groups [(295.7 ± 5.3 ; 235 ± 2.88 gms, respectively, for 2 days group) and (297.7 ± 6.02 ; 238.5 ± 2.6 gms,

respectively, for 21 days insulin replacement group)] (Fig. 4).

Leptin concentration, insulin and body weight relationship in the control male and female groups:

A strong positive correlation was observed between leptin concentration and body weight in control male and female rats groups ($r = +0.75$; $+0.73$, respectively, $P < 0.001$).

Moreover, a strong positive correlation was also found between leptin concentration and insulin hormone level in control male ($r = +0.76$) and in control female ($r = +0.9$) rats groups ($P < 0.001$). Hence, it is clearly apparent that serum leptin concentration change in a direct proportion to the variation in body weight and insulin hormone serum level in the control group.

Leptin concentration, body weight, insulin and blood glucose concentration relationship in diabetic (untreated) groups:

Serum leptin level showed very highly significant direct correlation with body weight ($r = +0.7$; $+0.77$) and a significant direct correlation with serum insulin level ($r = +0.7$; $+0.71$) in male and female groups respectively, and highly significant inverse correlation with blood glucose level in male and female groups ($r = -0.75$; -0.71 , respectively).

The positive correlation found between leptin concentration and body weight and insulin level in this study (in

the diabetic group) revealed a significant rise of leptin concentration with the increase of body weight and serum insulin level. Moreover, leptin was found to be change in an inverse proportion to the variation in blood glucose concentration in both male and female diabetic groups.

Leptin concentration, insulin and blood glucose concentration relationship in the male and female diabetic rats treated with insulin replacement therapy for 2 and 21 days:

Serum leptin level concentration in male groups, showed insignificant direct correlation ($r = +0.41$) with serum insulin level and insignificant correlation with blood glucose level ($r = -0.03$) for 2 days insulin replacement therapy.

On the other hand, serum leptin level showed very highly significant direct correlation ($r = +0.85$) with serum insulin level and highly significant inverse ($r = -0.66$) with blood glucose level for 21 days of insulin replacement. While, in female groups, serum leptin level showed highly significant direct correlation ($r = +0.68$) with serum insulin level and insignificant inverse correlation with glucose level ($r = -0.26$) for 2 days insulin replacement. Moreover, serum leptin level showed very highly significant direct correlation ($r = +0.75$) with serum insulin level and highly significant inverse correlation with blood glucose ($r = -0.78$) for 21 days insulin replacement.

Table (1): Comparison between serum leptin concentration (ng/ml) in male and female albino rats in all studied groups.

Groups	Control		Diabetic group		Diabetic treated insulin replacement (2 days)		Diabetic treated insulin replacement (21 days)	
	Male	Female	Male	Female	Male	Female	Male	Female
Leptin concentration (ng/ml) $\bar{X} \pm$ S.E sig.	1.25 \pm 0.03	1.80 \pm 0.052 P<0.001	0.46 \pm 0.042	0.56 \pm 0.066 n.s.	1.02 \pm 0.05	1.1 \pm 0.07 n.s.	1.52 \pm 0.12	1.6 \pm 0.1 n.s.

P<0.001 = Very highly significant.

n.s. = not significant.

Table (2): Serum leptin concentration (ng/ml), insulin hormone level (μ IU/ml), blood glucose level (mg/dl) and body weight (gms) in all studied groups of male rats.

Parameters	Control group (G ₁)	Diabetic (untreated) (G ₂)	Insulin replacement 2 days (G ₃)	Insulin replacement 21-days (G ₄)
Leptin conc. (ng/ml) $\bar{X} \pm$ S.E Sig.	1.25 \pm 0.05	0.46 \pm 0.042 P<0.001	1.02 \pm 0.05 P<0.001	1.52 \pm 0.12 P<0.001
Insulin level (μ IU /ml) $\bar{X} \pm$ S.E Sig.	30.4 \pm 1.4	1.5 \pm 0.56 P<0.001	51.4 \pm 4.8 P<0.001	97.4 \pm 6.4 P<0.001
Blood glucose (mg/dl) $\bar{X} \pm$ S.E. Fig.	89.5 \pm 4.2	342.7 \pm 34.5 <0.001	70.2 \pm 5.04 P<0.001	60.5 \pm 2.3 P<0.001
Body weight (gms) $\bar{X} \pm$ S.E. Sig.	305.3 \pm 3.6	271.8 \pm 6.3 P<0.001	295.7 \pm 5.3 P<0.01	297.7 \pm 6.02 P<0.01

P<0.01 = highly significant.

P<0.001 = very highly significant.

Table (3): Serum leptin concentration (ng/ml), insulin hormone level (μ IU/ml), blood glucose level (mg/dl) and body weight (gms) in all studied groups of female rats.

Groups Parameters	Control group (G ₁)	Diabetic (untreated) (G ₂)	Insulin replacement 2 days (G ₃)	Insulin replacement 21- days (G ₄)
Leptin conc. (ng/ml) X ⁻ ±S.E Sig.	1.80±0.052	0.56±0.066 P<0.001	1.1±0.07 P<0.001	1.6±0.1 P<0.001
Insulin level (μ IU /ml) X ⁻ ±S.E Sig.	31.3±2.56	1.36±0.4 P<0.001	56.4±5.8 P<0.001	86.3±7.4 P<0.001
Blood glucose (mg/dl) X ⁻ ±S.E. Fig.	92.8±4.9	338.5±21.6 P<0.001	72.0±4.4 P<0.001	66.8±2.8 P<0.001
Body weight (gms) X ⁻ ±S.E. Sig.	242.7±7.5	214.7±7.4 P<0.05	235.0±2.88 P<0.01	238.5±2.6 P<0.01

P<0.01 = highly significant.

P<0.001 = very highly significant.




Fig. (1): Serum leptin level (ng/ml) in all studied groups of male and female albino rats.




Fig. (2): Serum insulin level (µIU/ml) in all studied groups of male and female rats.




Fig. (3): Blood glucose level (mg/ml) in all studied groups of male and female rats.




Fig. (4): Body weights (gms) in all studied groups of male and female rats.

Discussion

Leptin, a 167 amino acid protein transcribed from the obesity (*ob*) gene in the adipose tissue, was originally cloned in the mouse during research directed at identifying the molecular defect in obesity-prone strain (*ob/ob* mouse) (Zhang *et al.*, 1994). The two most important parameters accounting for variations in leptin concentrations are sex and the amount of body fat (Considine *et al.*, 1996).

The present study showed that female rats had significantly higher mean values of serum leptin levels than males in the control group. These data are consistent with results from previous studies in experimental animals (Yacout *et al.*, 200) and humans (Kieiss *et al.*, 1998). The gender difference in serum leptin concentrations was also previously described in adults (Danne *et al.*, 1997) and pediatric (Lahlou *et al.*, 1997) healthy subjects, young patients with IDDM (Verotti *et al.*, 1998).

Therefore, it could be concluded that gender seems to be important for the variation in the serum leptin concentration in adult normal rats. However, various factors such as the changes in blood glucose, insulin concentration, and pattern of feeding have emerged which appear to dominate the influence on leptin concentration other than gender. The most likely explanation for this difference is the greater adipose tissue mass in females than males whereas the muscle is greater in males than females. Besides this sex difference in body composition direct influence of sex steroids may be causative (Blum *et al.*, 1997).

Numerous studies have reported the importance of sex steroids to account for the different leptin concentrations according to sex, and the existence of a negative correlation between testosterone concentrations and serum leptin concentrations in men (Elbers *et al.*, 1997).

and Yacout *et al.*, 2000), although others have not found thin correlation and suggested that, in men, sex hormones are not important independently modifiers of leptin concentrations (Haffner *et al.*, 1997). However, Tuominen *et al.* (1997) found a negative correlation between leptin and testosterone in a study of male patients with type-1 diabetes mellitus, but not in controls. In the study of Martines *et al.* (2000), it was found that leptin concentrations in women were more than twice those in men despite the similarity of BMI values in both studied groups. They also failed to find a correlation between leptin concentrations and testosterone in the men with type-1 diabetes mellitus.

It was also found, in the present study, that there is no gender difference in serum insulin concentration in the control group. This finding demonstrates that insulin concentration could not be a factor explaining the gender difference in leptin concentration. In the present study, strong positive correlation was found between leptin concentration and body weight in the control male and female groups. Moreover a strong positive correlation was also found between leptin concentration and insulin hormone level in control male and female groups.

These findings clearly demonstrate that serum leptin concentration change in a direct proportion to the variation in body weight and insulin hormone serum level in the control group i.e. adult normal rats whether male or female, with high body weight or high serum insulin level had a higher serum leptin concentration than rats with low body weight and low serum insulin level.

These findings are consistent with previous studies recorded on the effect of body weight (Considine *et al.*, 1995 and Niklas *et al.*, 1997) and serum

insulin level (Havel *et al.*, 1996) on serum leptin concentration.

The present study revealed that streptozotocin induced diabetes resulted in a significant weight loss and a marked reduction in serum leptin concentration which was partially but significantly reversed after 2 days of insulin therapy and completely reversed to baseline (prediabetic) levels or may even overshoot above the base line after 21 days of insulin therapy. These findings are in agreement with the results of Sivitz *et al.* (1998) who observed that the reversal of the significantly reduced plasma leptin concentrations by insulin treatment of streptozotocin diabetic rats occurred before the return of the significantly reduced body weight or epididymal fat mass to baseline (prediabetic) levels. Hence, they suggested that insulin itself increased leptin concentrations independently of altered adipose mass.

Havel *et al.* (1998) found that leptin was markedly decreased in STZ diabetic rats as early as 24 hours to 48 hours after the induction of diabetes, but, before major decrease in body weight. They also, observed that plasma leptin was significantly decreased after 2 weeks and remained low through 12 weeks of STZ diabetes in rats with significantly lower body weight. They reported that the early changes of leptin were proportional to the changes of glycemia but not to changes of body weight. They attributed the weight loss during the first 24 hours to 48 hours after induction of diabetes mostly to loss of body water rather than body fat. In addition, Havel *et al.* (1998) showed that plasma leptin levels were increased by insulin treatment of STZ diabetic rats in proportion to the reduction of hypoglycemia.

In the present study, low leptin

levels are present in diabetic rats before insulin treatment was begun is also in accordance with that of Kiess *et al.* (1998) who found that low leptin levels even after adjustment for body mass index (BMI), were present at clinical presentation of diabetes in a small cohort of children and adolescent with IDDM before insulin treatment was started.

There are several possible explanations for this finding: (1) low leptin levels in diabetic animals and/or in-patients with newly onset diabetes might be related directly to the absent or low insulin levels. In fact, data from animal experiments suggest that insulin directly induces leptin expression, pointing to insulin as an important regulator of leptin (Leroy *et al.*, 1996).

In addition, STZ related mice have reduced leptin mRNA levels which are partially restored by insulin treatment (Mizuno *et al.*, 1996). Many investigators reported that the decrease in plasma leptin in STZ diabetic rats was observed to be consistent with the decrease in epididymal adipose tissue leptin mRNA levels (Sivitz *et al.*, 1996 and Havel *et al.*, 1998). Backer *et al.* (1995) reported a decrease in subcutaneous (inguinal) adipose leptin mRNA in STZ diabetic rats. This decrease in leptin mRNA was not rapidly reversible by insulin therapy and restoration to baseline (non diabetic) levels does not occur in rats prior to restoration of body weight (Baker *et al.*, 1995 and Sivitz *et al.*, 1996). Moreover, Sivitz *et al.* (1998) observed that the reduced body weight, epididymal fat mass, and epididymal adipose mRNA in STZ-diabetic rats did recover at least, to baseline when insulin therapy was continued for 17 days.

Hence, they suggested that the increase in plasma leptin induced by insulin therapy does not depend on

steady state message levels within adipose tissue depots but may depend on posttranscriptional cellular events regulating the translations, intra-cellular pooling, or peptide release or altered clearance of circulating leptin.

Insulin treatment has been previously demonstrated to increase ob mRNA in nondiabetic rats (Saladin *et al.*, 1995) and normalize ob mRNA expression in some (MacDougard *et al.*, 1995) but not all (Kolaczynski and Caro, 1996) studies of STZ diabetic rats. Although, it has been suggested that insulin could have a direct effect on leptin production and/or leptin expression (Caro *et al.*, 1996), studies performed in whole rats and primary rat adipocytes have not always demonstrated a clear insulin effect on ob gene expression in STZ diabetic rats (Kolaczynski and Caro, 1996).

In humans, however, reports on the influence of insulin on leptin are conflicting. While in some studies in human leptin levels were not influenced by hyperinsulinemia (i.e. euglycemia clamp with steady state hyperinsulinemia from 80-120 μ IU/ml maintained for up to 5 h) and meal-related increases in circulating insulin levels (Muscelli *et al.*, 1996) although leptin levels showed a definite nocturnal rise in lean, obese, and diabetic subjects. Malmstrom *et al.* (1996) by using hyperinsulinemic clamps have also shown that insulin significantly stimulated serum leptin concentrations in man (patients with non IDDM).

In the study of Muscelli *et al.* (1996), the acute administration of insulin in physiological amounts and under euglycemic conditions did not change circulating leptin levels in lean, or obese subjects. Also, the data of Larsson *et al.* (1996) confirm that it is unlikely that insulin increases plasma leptin even at high circulating levels.

Verroti *et al.* (1998) showed that leptin concentrations in diabetic patients treated with human insulin were similar to those in non-diabetic subjects. They attributed this finding to adequate metabolic control by intensive insulin treatment. It is well known that in diabetic patients with poor metabolic control, abnormalities of thyroid hormones, growth hormone binding proteins and other hormones are frequently detected (Adcock *et al.*, 1994). In contrast, in diabetic patients with improved metabolic control, normalization of the above abnormalities is generally attained (Caro *et al.*, 1996).

On the other hand, Tuominen *et al.* (1997) stated that fasting leptin levels were higher in IDDM subjects and remained unchanged during (acute) hyperinsulinemia (i.e. 4h.euglycemic hyperinsulinic clamp). These authors suggested that patients with IDDM are resistant to insulin action on leptin synthesis. The most direct proof, however, that insulin stimulates leptin expression and synthesis in humans stems from *in vitro* studies with differentiated human adipocytes (Wabitsch *et al.*, 1996).

The present study demonstrated that the increase in plasma leptin in insulin treated STZ diabetic rats was evident as early as 2 days, while the study of Sivitz *et al.* (1996) showed that leptin mRNA remained well below the prediabetic levels after 2 days of insulin treatment and Backer *et al.* (1995) found that leptin mRNA in STZ diabetic rats treated with insulin up to 4 days still remained below the levels in non diabetic rats. Hence, in the present study, current 2 days plasma leptin results considered along with past studies of leptin message support the concept of a disaccordance (disparity between circulating leptin and leptin

message (leptin mRNA) in insulin treated diabetic rats).

However, Calpham *et al.* (1997) measured plasma leptin and subcutaneous adipose tissue leptin mRNA in non-diabetic lean and obese humans before and after a mixed meal and observed no change in either parameter despite a substantial increase in plasma insulin. However, there may be species differences in the rate of leptin response to insulin, or insulin mediated leptin release as, whereas the human studies imply that *in vivo* leptin responsiveness to insulin requires prolonged insulin administration, the results of the present study together with others (Sivitz *et al.*, 1998) observed a rapid and substantial increase in leptin in STZ-diabetic rats. Certain factors could explain the discrepancy in insulin responsiveness between rodents and humans. It is known that insulin-induced glucose flux, measured as whole body glucose utilization, is higher in rodents than in humans even at equivalent glycemia (Kraegen *et al.*, 1983). Hence, there may be a critical degree of insulin-induced energy uptake beyond which leptin release is triggered.

Dissociation between changes of ob gene expression and changes of circulating leptin concentrations has been reported. For example, plasma leptin increases after increase dexamethazone administration in humans without a corresponding increase of adipose mRNA (Kolaczynski and Caro, 1996).

It should be noted that the circulating insulin concentrations produced by administering exogenous insulin to diabetic rats in these studies were substantially higher than in non diabetic control animals. These levels are, however, necessary to lower plasma glucose concentrations because STZ diabetes is associated with insulin

resistance (Nishimura *et al.*, 1989) in addition to insulin deficiency.

No strict correlation between insulin dose and plasma insulin was detected in diabetic patients because many different factors contribute to the modifications of plasma levels (route of administration, variability of absorption, kinetics of circulation) (Brunetti and Bolli, 1997).

Our study showed a positive correlation between serum leptin levels and serum insulin concentrations in both control and STZ diabetic rats. Several studies have revealed an association between insulin and leptin in both animals (Wabitsch *et al.*, 1996) and humans (Saad *et al.*, 1998), although others found no association between insulin and leptin in obese persons (Dagogo-Jack *et al.*, 1996). In the study carried out by Martinez *et al.* (2000) in type-1 diabetic adults, no relation was found between leptin concentrations and daily insulin dose. A recent study found that leptin concentrations correlated significantly with insulin dose in prepubertal children, but not during puberty (Moll *et al.*, 1998), although others, did not find this correlation in children with type 1 diabetes mellitus followed from the onset of their diabetes and after several weeks of insulin treatment (Ross *et al.*, 1998). This lack of a significant correlation between insulin dose and leptin concentrations was also noted by Tuominen *et al.* (1997) in adult patients with type-1 diabetes mellitus.

(2) Alternatively, very high blood glucose concentrations in cases of diabetes mellitus could also suppress leptin levels. However, data regarding a putative regulation of leptin expression by glucose are conflicting. In mice and humans, ob mRNA was inhibited by food restriction associated with glucopenia and was stimulated by

injections of glucose in some (Ostlund *et al.*, 1996) but not in other studies (Funahashi *et al.*, 1995).

In the present study, a negative correlation between serum glucose and leptin concentrations was found. Kiess *et al.* (1998) found no correlation between serum glucose and leptin concentrations in IDDM patients receiving insulin. Verrotti *et al.* (1998) found no significant correlation between blood glucose level and leptin in either control or diabetics treated with insulin (obese and non obese).

Many physiological studies suggested that variations in blood glucose are not an active signal for leptin secretion (Lahlou *et al.*, 1997). A number of published studies have found that short term insulin administration does not increase plasma concentrations in human subjects (Dagogo-Jack *et al.*, 1996).

In contrast, some other studies have demonstrated significant increases of circulating leptin concentrations after 4-6 h. of high dose insulin and glucose infusion in non diabetic (Utriainen *et al.*, 1996) and diabetic human subjects (Havel *et al.*, 1996).

Furthermore, infusions of glucose alone, resulting in hyperglycemia, and concomitant endogenous hyperinsulinemia, increases plasma leptin within 4h in humans (Sonnenberg *et al.*, 1996). There is evidence that the induction of marked hyperinsulinemia is not required to increase plasma leptin concentrations. For example, low dose glucose infusion sufficient to prevent the decline of plasma insulin and glucose during fasting also prevents the decline of plasma leptin (Boden *et al.*, 1996). In addition, lowering plasma glucose concentrations to euglycemia in hyperglycemic insulin-dependent diabetic human subjects by infusing insulin at

rates that produced physiological insulinemia increases circulating leptin (Havel *et al.*, 1996).

Therefore, an effect of insulin to increase adipose tissue glucose uptake and metabolism, rather than hyperinsulinemia per se may be involved in stimulating leptin secretion (Havel *et al.*, 1998). Consistent with this hypothesis, Mueller *et al.* (1998) have found that stimulation of leptin secretion by insulin from *in vitro* cultured rat adipocytes is closely related to the effects of insulin to increase adipocyte glucose uptake. In the same study, blocking glucose uptake with 2-deoxy-Dglucose, phloretin, or cytochalasin-B or inhibiting glucose metabolism with iodoacetate or sodium fluoride produced inhibitions of leptin secretion that were related to decreased glucose utilization, despite the presence of high insulin concentrations. Thus, hypoleptinemia in un-regulated insulin-deficient diabetes may be a consequence of decreased glucose uptake and metabolism in adipose tissue, whereas the restoration of circulating leptin levels by insulin treatment in diabetic animals may be secondary to increased adipocyte glucose uptake and utilization.

(3) Diabetic animals before the initiation of insulin treatment had low body weight values that were also significantly lower than body weight values in treated diabetic animals. Thus a reduced body fat mass due to increased lipolysis following insulin deficiency might have resulted in reduced absolute leptin levels in untreated diabetic animals (Kiess *et al.*, 1998). Moreover, assuming that the reduced body weight of diabetic animals was, in part, also due to dehydration (Havel *et al.*, 1998), the calculation of leptin would over-rather than underestimate leptin values with respect to fat mass. Furthermore, the

present study, in agreement with that of Kiess *et al.* (1998), demonstrated a positive correlation between serum leptin levels and body weight or (BMI), and insulin. Sivitz *et al.* (1998) suggested that the absolute level of adipose cell energy storage may not be as critical for fat cell leptin release as the level of circulating insulin or the rate of insulin-induced energy entry or energy flux. These findings suggest, therefore, that insulin may indeed be an important regulator of leptin levels.

(4) Potential effects of other insulin or glucose responsive factors in modulating the leptin response to insulin in this *in vivo* study can not be excluded. In particular serum cortisol, which is known to stimulate adipose leptin production, may have played a role (De-Vos *et al.*, 1995). However, this would be more likely to occur in hypoglycemia.

In conclusion, the present study revealed that: 1-Gender is one of the physiological factors which affect circulating leptin level. 2-Since, plasma leptin concentrations are volatile in insulin treated diabetic rats, being markedly reduced under conditions of insulin deficiency and rapidly reversed with insulin treatment, insulin is one of the most important factors in the regulation of circulating leptin level. 3-As leptin concentration was found to correlate directly with insulin level and body weight but inversely with blood glucose level, factors other than insulin are involved in the physiological regulation of circulating leptin concentration such as body weight and blood glucose level.

References

1. Adcock, C.J., Perry, L.A., Lindsell, A.M., Taylor, A.M., Holly, J.M. and Jones, J. (1994):

- Menstrual irregularities are, more common in adolescents with type II diabetes: association with poor glycemic control and weight gain. *Diabetic Medicine*, 11 : 465-470.
2. **Ahren, B.; Mansson, S.; Ronald, L.G. and Havel, P.J. (1997):** Regulation of plasma leptin in mice: Influence of age, high fat diet and fasting. *Am. J. Physiol.*, 273:R113-R120.
 3. **Auwerx, J. and Staels, B. (1998):** Leptin. *The lancet* 351 (March 7): 737-742.
 4. **Backer, D.J., Ongemba, V., Brichard, V., Henquin, J.C., and Brichard, S.M. (1995):** Diet and diabetes induced changes of ob gene expression in rat adipose tissue *FEBS Lett.* , 371: 324-328.
 5. **Blum, W.E., Englaro, P., Hanitsch, S., Juul, A.& Hertel, T.N, Skakkebaek, N.B. , Attanasio, A. and Rascher, W. (1997):** Serum leptin levels in healthy children and adolescents: dependence in body mass index, gender and developmental stage. *J. Clin. End. & Metab.*, 82: 2904-2910.
 6. **Boden, G., Chen, X., Mozzoli, M., and Ryan, I. (1996):** Effect of fasting on serum leptin in normal human subjects. *J. Clin. Endocrinol. Metab.*, 81: 3419-3423.
 7. **Brunetti, B., and Bolli, G.B. (1997):** Pharmacokinetics and pharmacodynamics of insulin: relevance to the therapy of diabetes mellitus . *Diabetes Nutrition & Metabolism*, 10: 24-34
 8. **Calpham, J.C., Smith, S.A. and Moore, G.B. (1997):** Plasma leptin concentrations and ob gene expression in subcutaneous adipose tissue are not regulated acutely by physiological hyperinsulinemia in lean and obese human. *Int. J. Obs. Rel. Metab. Disord.*, 21: 179- 183.
 9. **Caro, J.R., Sinha, M.K., Kolaczynski, J.W., Zhang, P.L. and Considine, R.V. (1996):** Leptin the tale of an obesity gene. *Diabetes*,45: 1455-1462.
 10. **Considine, R.V., Sinha, M.K., Heiman, M.L., Heiman, M.L., Kriauciunas, A., Stephans, T.W., Nyce, M.R., Ohannesian, J.P., Marco, C.C., Mckee, L.J., Bauer, T.I. and Caro, J.F. (1996):** Serum immunoreactive leptin concentrations in normal weight and obese humans. *N. Engl. J. Med.*, 334: 292-295.
 11. **Dagogo-Jack S., Fanelli, C., Paramore, D., Brothers, J. and Landt, M. (1996):** Plasma leptin and insulin relationship in obese and non-obese humans. *Diabetes* , 45: 695-698.
 12. **Danne, T., Gruters, A., Wladimirova, A., Weber, B., Horn R. and Mayr, B.(1997):** Gender specific differences of serum leptin in obese and normal weight adolescents: Studies in type -1 diabetes and Turner syndrome. *Horm. Research*, 48: 103-107.
 13. **De-Vos, P., Saladin, R., Auwex, J. and Staels, B. (1995):** Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. *J. Biol. Chem.*, 27: 15958-15961.
 14. **Dubuc, G.R., Stephen, D.P., Stern, J.S., and Havel, P.J. (1998):** Changes of serum leptin and endocrine and metabolic parameters after 7 days of energy restriction in men and women. *Metabolism*, 47 (4): 429-434.
 15. **Elbers, J., Asschemal, H., Seidel, J., Frplich, M. and Gooren L. (1997):** Reversal of sex differences in serum leptin levels upon cross sex hormone administration in transsexual. *J. Clin. Endoc. Metab.*, 82:3267-3270.

16. **Erickson J., Clegg, K. and Palmiter, R. (1996):** Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. *Nature*, 381: 415-418.
17. **Funahashi, S., Vimelli, S. and Kuhn, C.M. (1998):** Muscarinic stimulation and antagonism and glucoregulation in non diabetic and obese hypoglycemic mice. *Diabetes*, 38:1433-1438.
18. **Hamilton, B.S.; Laglia, D.; Kwan, A.Y. and Deited, M. (1995):** Increased obese mRNA expression in omental fat cells from massively obese humans. *Nature Med.*, 1:953-956.
19. **Havel, P. J., Kasim – Karakas S., Mueller W., Johnson P.R., Gingerich R. L., and Stern J.S. (1996):** Relation-ship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women:: Effects of dietary fat content and sustained weight loss. *J. Clin. Endocrinol. Metab.*, 81: 4406-4413.
20. **Havel, P.J., Hare, J.Y., Liu, T., Stanhope Stern J.S., Keen, C.L., and Ahren,B. (1998):** Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin *Am. J. physiol.*, 274 : R1482-R14891
21. **Haffner, S., Miettinen, H. Karhapa, P., Mykanen, L. and Lakso, M.(1997):** Leptin concentrations, sex hormones, and cortisol in nondiabetic men. *J. Clin. Endoc.*, 82: 1807-1809
22. **Harry, P.K., Santarosa, R.P., Butyan R., Shabsigh, R., Olson, C.A., and Kaplan ,S.A. (1993):** Early molecular changes associated with STZ-induced diabetic bladder hypertrophy in rat. *Urological Research.*, 21: 375-381.
23. **Huszar, D., Lynch, C.A. and Fairchild-Huntress, V. (1997):** Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell* , 88: 131-141.
24. **Kiess, W.; Anil, M.; Blum, W.F.; Englaro, P. et al. (1998):** Serum leptin levels in children and adolescents with insulin dependent diabetes mellitus in relation to metabolic control and body mass index. *Eur. J. Endoc.*, 138:501-509.
25. **Kolaczynski, J.W. and Caro, J.F. (1996):** Molecular mechanism of insulin resistance in human obesity. *Diabetes*, 3: 36-43,
26. **Kragen, E.W.; James, D.E. and Benett, S.B. (1983):** *In vivo* insulin sensitivity in the rats determined by euglycemic clamp. *Am. J. Physiol.*, 245: E1-E37.
27. **Lahlou, N., Landais, B., De Boissieu, D., and Bougneres, B.F. (1997):** Circulating leptin in normal children and during the dynamic phase of juvenile obesity. Relation to body fatness, energy metabolism, caloric intake and sexual dimorphism, *Diabetes*,46: 989-993.
28. **Larsson, H., Elmstahl, S. and Ahren, B. (1996):** Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women. *Diabetes.*, 45: 1581-1584.
29. **Leroy, P., Dessolin, S., Villageois, P., Moon, B.C., Friedman, J.M., Ailhaud, G. and Dani,C.(1996):** Expression of ob gene in adipose cells: regulation by insulin . *J. Biol. Chem.*, 271:2365-2368
30. **Lutz, A.J. and Pardridge, W.M. (1993):** Insulin therapy normalizes GLUT1 glucose transporter mRNA but not immunoreactive transporter protein in streptozocin- diabetic rats. *Metabolism*, 42: 939-944.

31. **MacDougard, O.A.; Hwang, C.S.; Fan, H. and Lane, M.D. (1995):** Regulated expression of the obese gene product (Leptin) in white adipose tissue and 3T3-L1 adipocytes. *Proc. Natl. Acad. Sci. U.S.A.*, 92:9043-9037.
32. **Malmstrom, R., Taskinen, M.R., karonen, S.L. and Ykijarvinen, H. (1996):** Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. *Diabetologia.*, 39:993-996.
33. **Martinez, G.R., Soriguer, F.J., Gonzalez-RAmero ,S., Tnahons,E. , Moreno F, Ruiz de Adana, S. , Garriga, M.J., Esteva, I. and Garcia-Almedia, M. (2000):** Serum leptin and habitual fatty acid dietary intake in patients with type 1 diabetes mellitus *Eur. J. of Endocrin.*, 142: 263-268.
34. **Mizuno, T. M., Bergen, H., Funabashi, T., Kleopoulos, S. P, Zhong, Y. G., Bauman, W. A., and Mobbs, C. V. (1996):** Obese gene expression: reduction by fasting and stimulation by insulin and glucose in lean mice, and persistent elevation in acquire (diet induced) and genetic (yellow agouti) obesity. *Proc. Natl. Acad. Sci. USA.*, 93: 3434-3438
35. **Moll, G., Britt, R., Welch, D. and West, S. (1998):** Leptin levels reflect total daily insulin use in pubertal and prepubertal IDDM patients. *Diabetes*, 47: A404-7.
36. **Mueller, W.M., Gregoire, H., Stanhope, K.L., Mobbs C.V., Mizuno, T.M., Warden, C.H., Stern, J.S. and Havel, P.J. (1998):** Evidence that glucose metabolism regulates leptin secretion from cultured adipocytes. *Endocrinology*, 139: 551-581.
37. **Muscelli, E. , Camastra, S., Masoni, A., Baldi, S., Sironi, A.M., and Natali, A.(1996):** Acute insulin administration does not affect plasma leptin levels in lean and obese subjects. *Eur. J. of clinical Investigaytion*, 26: 940-943
38. **McGregor. G.P., Desaga, J.F., Ehlenz K., Fischer A., Heese F. and Hegele A. (1996):** Radioimmunity measurement of leptin in plasma of obese and diabetic human subjects. *Endocrinology*; 137:1501-1304.
39. **Nicklas, B.J., Katzel, L.I. and Ryan, A.S. (1997):** Gender differences in the response of plasma leptin concentrations to weight loss in obese older individuals . *Obes. Res.*, 5: 62-68.
40. **Nishimura, H.; Kuzuya, H.; Okamata, M., Yamada, A. et al. (1989):** Post receptor defect in insulin action in STZ induced diabetic rats. *Am. J. Physiol.*, 256:E624-E630.
41. **Ostlund, R.E., Yang, J.W., Klein, S., and Gingerich, R. (1996):** Relation between plasma leptin concentration and body fat, gender, diet, and metabolic covariates *J. Clin. Endocrinol. Metal.*, 81: 3909-3913.
42. **Ross, H.; Mick, G.; Parton, E.; Totka, J.; Butterfield, J. and McCormick, K. (1998):** Leptin levels in newly-diagnosed type-1 diabetic children before and following insulin therapy. *Diabetes*, 47:A408.
43. **Saad, M.F., Riad-Gabriel, M.G. and Khan, A. (1998):** Diurnal and ultradian rhythmicity of plasma leptin: Effects of gender and adiposity. *J Clin Endocrinol Metab.*,83: 453-459.
44. **Saladin, R., Staels, B., Auwerx, J., and Briggs, M. (1996):** Regulation of ob gene expression in rodents and humans. *Horm. Metab. Res.*, 28: 638-641.

45. **Sivitz, W.I., Bailey, H.L., and Donohoue, P. (1996):** Rat adipose ob mRNA levels in states of altered circulating glucose and insulin. *Biochem. Biophys. Res. Commun.*, 220: 520-525.
46. **Sivitz, W.I., Walsh, S., Morgan, D., Donohoue, B., Haynes, W. and Leibel, L. (1998):** Plasma leptin in diabetic and insulin treated diabetic and normal rats. *Metabolism*, 47: 584-591.
47. **Sonnenberg, G.E., Krakower, G.R., Hoffmann, R.G., Mass, D.L., Hennes, M.M.I. and Kissebah, A.H. (1996):** plasma leptin concentration : effects of extended fasting and stepwise increases in glucose infusion (abstract). *Obesity Res.*, 4: 135.
48. **Spina, M., Merlo-Pich, E. and Chan, R.K. (1996):** Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. *Science*, 273: 1561-1564.
49. **Tuominen, J.A., Ebeling, P. and Stenman, U.H. (1997):** Leptin synthesis is resistant to acute effect of insulin in IDDM patients. *J. Clin Endoc. Metab.*, 82: 381-382.
50. **Utriainen, T., Malmstrom R., Nakimattila S., and Yki-Jarvinen H. (1996):** Supra-physiological hyperinsulinemia increases plasma leptin concentrations after 4h in normal subjects. *Diabetes*, 45: 1364-1366.
51. **Verrotti, A., Basciani, F., Morgese, G. and Chiarelli, F. (1998):** Leptin levels in non obese and obese children and young adults with type 1 diabetes mellitus. *Eur. J. Endoc.*, 139: 49-53.
52. **Wabitsch, M., Jensen, P. B., Blum, W. F., Christoffersen, C.T., Englaro, P., Heinze E., Rascher, W., Teller, W., Tornqvist, H. T. and Hauner, H. (1996):** Insulin and cortisol promote leptin production in cultured human fat cell. *Diabetes*, 45: 1435-1438.
53. **Yacout, M.M., El-Ghannam, Abd-Allah, S. and Ibrahim K. (2000):** The role of gender and effect of gonadectomy and sex steroids (estradiol and testosterone) on the serum leptin level in rats. *Z.U.M.J. Special issue*, Nov: 403-422.
54. **Yamane T. (1970):** Statistics an Introductory analysis, 2 nd Edition. A Harper international edition over expressing leptin. *J. Clin. Invest.*, 105: 749-755.
55. **Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L. and Friedman, J. (1994):** Positional cloning of the mouse obese gene and its human homo-logue. *Nature*, 372: 425-432.

تأثير السكر المحدث تجريبيا علي مستوى الليبتين في مصل الدم ودور العلاج التعويضي بالأنسولين

نبيل عباس أحمد سليمان

قسم علم الحيوان – كلية العلوم – جامعة الزقازيق

لقد اكتشف حديثا ان الأنسجة الدهنية تفرز مادة تسمى الليبتين وقد وجد أنها تقلل الشهية للطعام وتزيد من استهلاك الطاقة وفي محاولة لإلقاء الضوء على بعض العوامل المؤثرة على إفراز الليبتين فقد صمم هذا البحث لدراسة تأثير مرض السكر التجريبي وهرمون الانسولين على نسبة الليبتين في حيوانات التجارب من ذكور وإناث الجرذان البالغة والتي تم تقسيمها الى أربعة مجموعات تتكون كل مجموعة من 12 جرذا (6 ذكور و6 إناث) كما يلي:

المجموعة الأولى : الضابطة

المجموعة الثانية : المصابة بمرض البول السكري المحدث تجريبيا باستعمال مادة الستربتوزوتوسين

المجموعة الثالثة والرابعة: المصابة بمرض البول السكري المحدث تجريبيا والتي تم معالجتها بالأنسولين لمدة يومين في المجموعة الثالثة ولمدة إحدى وعشرون يوما في المجموعة الرابعة.

هذا وقد أظهرت النتائج وجود ارتفاع ذو دلالة إحصائية في مستوى تركيز مادة الليبتين في مصل دم إناث الجرذان مقارنة بالذكور في المجموعة الضابطة ، بينما وجد أن هناك انخفاضاً ذو دلالة إحصائية في مادة الليبتين في حيوانات التجارب المصابة بمرض البول السكري مصحوبا بنقص ذي دلالة إحصائية في تركيز الأنسولين ووزن الجسم. وقد لوحظ عودة تركيز الليبتين حول معدله الطبيعي مع العلاج بالأنسولين لمدة يومين وإحدى وعشرون يوما.

وقد خلصت النتائج إلى أن هناك عوامل كثيرة تلعب دورا هاما في التأثير على مادة الليبتين في مصل دم الجرذان بالإضافة إلى التغيرات في وزن الجسم والتي يرتبط معها ارتباطاً طردياً من هذه العوامل :

1 -النوع (ذكر أم أنثى)

2 -مستوى السكر في الدم حيث وجد أن هناك ارتباطا عكسيا بين مستوى السكر في الدم وتركيز مادة الليبتين

3 -تركيز الأنسولين في الدم حيث وجد أن هناك ارتباطا طردياً بين مستوى الأنسولين والليبتين